[Dysbiotic manifestations during eradication therapy of Helicobacter pylori and their corrections].
Forty-eight patients with duodenal peptic ulcer disease infected with Helicobacter pylori were examined. All patients undergo conventional 1-week eradication therapy. After its ending the patients were randomized to two groups: those who will be treated by synbiotics or control group. Normoflorin B and Normoflorin L, which contain bifidobacteria or lactobacilli in complex with different microelements, vitamins, aminoacids, organic acids, and antioxidants, were used as synbiotics. Morphologic study of biopsy samples of small intestine mucosa were performed in patients from both groups. It was determined that eradication therapy worsened existing symptoms of dyspepsia in 80.9% of cases or lead to their emergence, connected with dysbiotic manifestations, in 55.5% of patients. Inclusion of synbiotics in complex therapy resulted in rapid and effective elimination of dyspeptic symptoms, promoted recovery of affected morphologic and functional states of small intestine mucosal epithelium, and optimized metabolic processes important for the digestion.
Eremina
E Iu
EIu
Bondarenko
V M
VM
Zvereva
S I
SI
Nikitina
O I
OI
Shaposhnikova
L I
LI
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001644:Bifidobacterium; D001706:Biopsy; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000150:complications* / Q000188:drug therapy; D004415:Dyspepsia / Q000473:pathology / Q000628:therapy; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D007410:Intestinal Diseases / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy; D007413:Intestinal Mucosa / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology; D007779:Lactobacillus acidophilus; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents